Thursday, April 25, 2013

Sanofi and Takeda to copromote Alogliptin in China

Sanofi and Takeda have entered into an agreement to  copromote Takeda's DPP-IV inhibitor Alogliptin in China.  As per the terms of the agreement, Sanofi will have the exclusive right to promote the drug in certain defined territories in China. Alogliptin is still awaiting SFDA's nod and is expected anytime this year. 
If approved Alogliptin would be the fifth DPP-IV inhibitor in China. The approved ones include Sitagliptin, Vildagliptin, Linagliptin and Saxagliptin.


Enter your email address:


Delivered by FeedBurner